Clinical Trials Logo
  1. Home
  2. Resistant Hypertension
  3. NCT06216808

A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension

Resistant Hypertension Clinical Trial

Official title:
A Prospective, Multicenter, Single Arm, Open Label, First-in-human Study to Evaluate the Safety and Initial Efficacy of HyperQureTM, Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension on 3 or More Antihypertensive Medications

Clinical Trial Summary

HQ-HTN-K01-02 is a prospective, multicenter, single arm, open label, first-in-human study to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic denervation therapy, in patients with resistant hypertension on 3 or more antihypertensive medications

Clinical Trial Description

< Study purpose > The purpose of this single arm interventional study is to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic renal denervation therapy, in patients with resistant hypertension on 3 or more antihypertensive medications including a diuretic < Background and Hypothesis > The HyperQureTM RDN(Renal Denervation) System is developed to overcome the limitations of endovascular RDN using catheters; 1)incomplete renal denervation, 2) risk of intimal damage due to intravascular access, and 3) access limitations due to vascular anatomy and size The HyperQureTM RDN System is accessed through the adventitia where renal sympathetic nerves are mainly distributed. Since energy is transmitted by wrapping the blood vessel 360 degrees, it is expected that it will be possible to achieve more complete renal denervation, reduce the risk of intimal damage, and solve structural access problems caused by the anatomy and size of the renal blood vessel. < Study plan > Ten eligible adult men and women with resistant hypertension will be enrolled and will have laparoscopic RDN under general anesthesia. CTA(Computed Tomographic Angiogram), blood tests, office blood pressure, 24-hour ambulatory blood pressure and QOL will be monitored to evaluate the safety and initial efficacy for 12 months after RDN procedure. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06216808
Study type Interventional
Source DeepQure Inc.
Contact Aeyoung Woo
Phone 82-10-7109-0205
Email aywoo@deepqure.com
Status Recruiting
Phase N/A
Start date June 14, 2023
Completion date June 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05545059 - Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension Phase 3
Not yet recruiting NCT04388124 - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION Phase 2
Withdrawn NCT01939392 - Rapid Renal Sympathetic Denervation for Resistant Hypertension II Phase 2/Phase 3
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting NCT05563077 - Aerobic Exercise and Resistant Hypertension N/A
Recruiting NCT03758196 - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension（RSDARH） N/A
Active, not recruiting NCT03179800 - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ N/A
Completed NCT04519658 - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) Phase 2
Not yet recruiting NCT05552300 - Superselective Adrenal Arterial Embolization for Resistant Hypertension N/A
Not yet recruiting NCT05426707 - Remote Ischemic Conditioning for the Treatment of Resistant Hypertension N/A
Completed NCT04345198 - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension N/A
Recruiting NCT05562934 - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. Phase 2
Recruiting NCT06034743 - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3
Withdrawn NCT02926495 - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension. N/A
Active, not recruiting NCT02670681 - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects N/A
Completed NCT02572024 - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study) N/A
Terminated NCT02295683 - Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
Completed NCT02001350 - Carotid Ultrasound Study N/A
Recruiting NCT04331691 - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension Phase 4